HLX18 (nivolumab biosimilar)
/ Fosun Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 19, 2025
Shanghai Henlius Biotech has received approval from the U.S. Food and Drug Administration for its investigational new drug application to begin a phase 1 clinical trial in the United States of HLX18, a nivolumab biosimilar designed as a recombinant anti-PD-1 humanized monoclonal antibody injection for multiple solid tumors.
(TipRanks)
IND • New P1 trial • Solid Tumor
1 to 1
Of
1
Go to page
1